相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
Zeynep Firtina Karagonlar et al.
CANCER SCIENCE (2016)
Hepatocyte growth factor and Met in drug discovery
Katsuya Sakai et al.
JOURNAL OF BIOCHEMISTRY (2015)
Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells
Hooi Ching Lim et al.
MOLECULAR CANCER (2015)
Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
Phillip B. Murray et al.
SCIENCE SIGNALING (2015)
Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?
C. Arnold Spek et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism
Guo-xing Zhong et al.
TUMOR BIOLOGY (2015)
Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK
Phillip B. Murray et al.
SCIENCE SIGNALING (2015)
HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation
Anna Spina et al.
BIOMEDICINES (2015)
miR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met
Peyda Korhan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside
Alessandro Furlan et al.
CANCER RESEARCH (2014)
Met as a therapeutic target in HCC: Facts and hopes
Silvia Giordano et al.
JOURNAL OF HEPATOLOGY (2014)
The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials: Reply
D. Sanford et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
MET inhibitors start on road to recovery
Ken Garber
NATURE REVIEWS DRUG DISCOVERY (2014)
Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma
Imge Kunter et al.
ONCOLOGY REPORTS (2014)
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial
Lorenza Rimassa et al.
HEPATIC ONCOLOGY (2014)
Low molecular weight heparin suppresses receptor for advanced glycation end products-mediated expression of malignant phenotype in human fibrosarcoma cells
Akihiko Takeuchi et al.
CANCER SCIENCE (2013)
MET: a promising anticancer therapeutic target
Solange Peters et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Heparin Inhibits Hepatocyte Growth Factor Induced Motility and Invasion of Hepatocellular Carcinoma Cells through Early Growth Response Protein 1
Evin Ozen et al.
PLOS ONE (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
c-Met Represents a Potential Therapeutic Target for Personalized Treatment in Hepatocellular Carcinoma
Hanning You et al.
HEPATOLOGY (2011)
Filamin A mediates HGF/c-MET signaling in tumor cell migration
Alex-Xianghua Zhou et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion
Murat Cokakli et al.
BMC CANCER (2009)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2009)
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular targeted therapies in hepatocellular carcinoma
Josep M. Llovet et al.
HEPATOLOGY (2008)
Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains
O. Holmes et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype
Pal Kaposi-Novak et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
PKC controls HGF-dependent c-Met traffic, signalling and cell migration
S Kermorgant et al.
EMBO JOURNAL (2004)
The Sema domain of Met is necessary for receptor dimerization and activation
M Kong-Beltran et al.
CANCER CELL (2004)
Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor
E Gherardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Novel drug development opportunities for heparin
R Lever et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor.
M Lyon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-Met interaction facilitates signaling
JS Rubin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
